<DOC>
	<DOCNO>NCT03002961</DOCNO>
	<brief_summary>A multi-center , open-label , single ascend dose study enroll opioid dependent treatment-seeking subject . Subjects enrol 3 cohort receive low , medium high dos depot buprenorphine . A fourth cohort enrol evaluate PK RBP-6000 receive suboxone tablet 7 day .</brief_summary>
	<brief_title>Single Ascending Dose Study RBP-6000</brief_title>
	<detailed_description>All subject undergo screen period 7 day . Eligible subject Cohorts 1-3 receive RBP-6000 dos conclusion screen . Subjects Cohort 4 receive sublingual ( SL ) Suboxone 7 day prior receive injection RBP-6000 . For cohort , subject admit clinic 2 day prior begin dose , remain clinic Day 21 . Blood collection hematology , chemistry serology analysis drawn screening , intermittently safety assessment study period . Subjects Cohorts 1-3 PK sample collect pre-dose serial PK collection post-dosing . Subjects Cohort 4 daily PK collection admit Suboxone dose serially RBP-6000 administration . Subjects return clinic PK sample collection Day 140 buprenorphine concentration fall 100 pg/mL . Subjects return clinic safety assessment Day 150 . Subjects experience sign symptom withdrawal prior RBP-6000 residential phase may receive non-opioid rescue medication . Subjects experience sign symptom withdrawal may receive hydromorphone begin Day 11 necessary . Methadone dose begin , clinically indicate , Day 16 subject administer hydromorphone . Subjects allow use buprenorphine time study . Subjects also receive psychosocial behavioral counseling specify PI . The End Study visit occur 1 week Day 84 1 week monthly follow-up visit Day 84 , give subject 's buprenorphine plasma concentration fall 100 pg/mL . For subject plasma concentration buprenorphine 100 pg/mL Day 140 , Day 150 End Study visit . Subjects enrol next cohort safety data least first 6 subject review .</detailed_description>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Sex : male female subject eligible entry . Age : ≥ 18 ≤ 65 year . Body mass index ( BMI ) ≥ 18.0 ≤ 33.0 kg/m2 Female subject must negative pregnancy test . Women child bear potential surgically sterile least 6 month prior dose must agree take reasonable precaution study avoid pregnancy agree remain abstinent practice one follow method birth control study screen last study visit : double barrier ( e.g. , diaphragm spermicide ; condom spermicide ) ; intrauterine device ( IUD ) ; implant intrauterine hormonal contraceptive use least 6 consecutive month prior study dose ; oral , patch , injected contraceptive vaginal hormonal device use least 3 consecutive month prior study . Meet DSMIVTR criterion opioid dependence seek opioiddependence treatment . ( Note : Subjects need seek treatment methadone willing accept methadone treatment consequence study . ) Normal clinically significant electrocardiogram ( ECG ) finding screen predose Day 1 . Total bilirubin ≤ 2x upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) ≤ 2xULN , aspartate aminotransferase ( AST ) ≤ 2xULN , serum creatinine ≤ 2xULN , international normalize ratio ( INR ) ≤ 2xULN . Agree take buprenorphine product administer current study ( SUBOXONE SL tablet RBP6000 ) throughout participation study . Willing cooperate study procedure provide write informed consent prior start study procedure . Require ongoing opioid therapy pain chronic medical condition . ECG demonstrate QTc &gt; 450 msec male QTc &gt; 470 msec female clinic entry prior administration RBP6000 . Currently dependent DSMIVTR criterion substance opioids , caffeine , nicotine . Currently ( past 30 day sign informed consent document ) engage opioid agonist , partial agonist , antagonist treatment ; require ongoing prescription counter ( OTC ) medication clinically relevant CYP P450 3A4 inducer inhibitor ( e.g. , rifampicin , azole antifungal [ e.g. , ketoconazole ] , macrolide antibiotic [ e.g. , erythromycin ] ) . See Appendix 12 excluded medication list . Significant traumatic injury , major surgery , open biopsy within prior 4 week inform consent . Buprenorphine use within 30 day inform consent . Subjects COWS score &lt; 12 day administration RBP6000 ( Applicable subject Cohort 13 , subject cohort 4 excluded COWS score &lt; 12 ) . Subjects history suicidal ideation within 30 day prior inform consent study drug administration evidence answer `` yes '' Questions 4 5 suicidal ideation portion CSSRS complete screen visit , history suicide attempt . Clinically significant abnormality past medical history screen physical examination opinion PI Sponsor may place volunteer risk interfere outcome variable include absorption , distribution , metabolism , excretion drug , include limited history concurrent cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic , psychiatric disease . History presence allergic adverse response ( include rash anaphylaxis ) buprenorphine , naloxone , methadone , ATRIGEL Delivery System . Donation &gt; 250 mL blood plasma participation another clinical trial within 30 day prior sign inform consent document study . Current use positive urine screen clinic admission barbiturate , benzodiazepine , buprenorphine , methadone . Serology positive human immunodeficiency virus ( HIV ) , acute hepatitis B , acute hepatitis C subject positive hepatitis B surface antigen ( HBsAg ) immunoglobulin M antibody hepatitis B core antigen ( antiHBc IgM ) . ( Note : Subjects asymptomatic hepatitis B C infection may enrol . ) All herbal supplement , grapefruit grapefruit juice , OTC medication . Sponsor may allow exception medicine unlikely impact PK PD result . Subjects previously exclude participation previously enrol study previously participate study RBP6000 . Subjects unable , opinion PI medically responsible physician , comply fully study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>